The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration.
The purpose of this study was to evaluate the oral absorption characteristics of a phospholipid-drug conjugate, comprising direct conjugation between the lecithin and the drug moiety through the sn-2 position. We investigated the mechanisms involved with the trafficking of this conjugate following oral administration in the gastrointestinal (GI) lumen, within the enterocyte and further. A phospholipid-valproic acid conjugate (DP-VPA) was utilized as a model molecule. The oral absorption of this conjugate in rats was investigated following administration in long (LCT) vs. medium (MCT) chain triglyceride formulations, and in the postprandial vs. fasted state. Oral administration within the LCT solution caused more than a 3-fold increase in DP-VPA bioavailability in comparison to the MCT solution. Moreover, a significant food effect was evident for DP-VPA. Hence, we evaluated the lymphatic transport of DP-VPA in mesenteric lymph duct cannulated freely moving rats. Sixty percent of the absorbed DP-VPA was associated with lymphatic transport. Similar DP-VPA absorption was obtained in secretory type II PLA(2) knockout mice (C57BL/6) and in control mice (BALB/c). Moreover, nil DP-VPA degradation in serum and very low (4.8%) degradation by bee venom PLA(2)in vitro were obtained. In conclusion, direct conjugation between the drug and the phospholipid produces a complex having unique absorption properties that include: (1) a stable complex that does not undergo degradation in the GI tract; (2) permeation through the gut wall and entering intact to the enterocyte; and (3) association with chylomicron in the enterocyte and reaching the systemic circulation via the lymphatic route. These unique properties may be of interest in drug delivery.
Dahan
Arik
A
Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Duvdevani
Revital
R
Shapiro
Israel
I
Elmann
Anat
A
Finkelstein
Elena
E
Hoffman
Amnon
A
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D001692:Biological Transport; D004337:Drug Carriers / Q000737:chemistry*; D004355:Drug Stability; D018565:Food-Drug Interactions; D007275:Injections, Intravenous; D054709:Lecithins / Q000737:chemistry*; D008196:Lymph / Q000378:metabolism; D042601:Lymphatic Vessels; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015394:Molecular Structure; D009061:Mouth Mucosa / Q000378:metabolism*; D054467:Phospholipases A2 / Q000235:genetics / Q000502:physiology; D019518:Postprandial Period; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000737:chemistry*; D014635:Valproic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics
C471110:DP-VPA; D004337:Drug Carriers; D054709:Lecithins; D011355:Prodrugs; D014280:Triglycerides; D014635:Valproic Acid; D054467:Phospholipases A2